Autopsy report · NCT00090870

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

“Pharmaceutical collaborator pulled funding.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 5 months after it had already started.
• Ran for about 7 years 11 months before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 8 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Medical University of South Carolina

Sponsor type

University, hospital or other

Conditions

Kidney Cancer

Interventions

PEG-interferon alfa-2b; GM-CSF; thalidomide

Participants

10

Sites

1

Countries

United States

Trials that died the same way

• CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
  “The pharmaceutical funder pulled funding and no longer plans to develop the drug further.” (70% match in meaning)
• A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
  “The entire drug development program for this molecule was sold to another company.” (69% match in meaning)
• A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
  “Sponsor's decision for the Drug Development.” (67% match in meaning)
• A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
  “Pharmaceutical company pulled support for the trial.” (66% match in meaning)
• A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
  “Pharmaceutical sponsor withdrew financial support.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.